Sézary Syndrome

• FDA approval · 2026-02-19
  FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)

  The FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) by Kyowa Kirin, Inc.

• FDA approval · 2025-01-21
  FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)

  FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc., as part of the drug's regulatory …

• FDA approval · 2024-08-07
  FDA Approved: LYMPHIR — Original Application (Citius Pharmaceuticals, Inc.)

  FDA approved LYMPHIR (denileukin diftitox-CXDL) through an original application for the treatment of CD25-expressing cutaneous T-cell lympho…

• FDA approval · 2022-04-27
  FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)

  FDA approved the original application for BEXAROTENE from Amneal Pharmaceuticals NY LLC.

• FDA approval · 2022-03-30
  FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)

  The FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-03-19
  FDA Approved: UVADEX — Supplemental Application (Therakos LLC)

  FDA approved a supplemental application for UVADEX (methoxsalen) from Therakos LLC.

• FDA approval · 2021-01-14
  FDA Approved: BEXAROTENE — Original Application (Actavis Pharma, Inc.)

  FDA approved Actavis Pharma, Inc.'s original application for generic Bexarotene. The drug is indicated for the treatment of cutaneous T-cell…

• FDA approval · 2018-12-11
  FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

  FDA approved a supplemental application for ZOLINZA (vorinostat) from Merck Sharp & Dohme LLC.

• FDA approval · 2018-09-04
  FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)

  The FDA approved Amneal Pharmaceuticals NY LLC's original-application generic of Bexarotene for cutaneous T-cell lymphoma.

• FDA approval · 2018-08-08
  FDA Approved: POTELIGEO — Original Application (Kyowa Kirin, Inc.)

  The FDA approved Poteligeo (mogamulizumab-kpkc) in the original BLA for adults with relapsed or refractory mycosis fungoides or Sézary syndr…

• FDA approval · 2018-05-08
  FDA Approved: BEXAROTENE — Original Application (ANI Pharmaceuticals, Inc.)

  ANI Pharmaceuticals received FDA approval for a generic bexarotene through an Original Application (ANDA). The product is indicated for the …

• FDA approval · 2014-12-02
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  FDA approved a supplemental application for Targretin (bexarotene) submitted by Bausch Health US, LLC.

• FDA approval · 2014-08-12
  FDA Approved: BEXAROTENE — Original Application (Mylan Pharmaceuticals Inc.)

  FDA approved Mylan's generic bexarotene for use in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome.

• FDA approval · 2013-07-22
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.

• FDA approval · 2009-11-05
  FDA Approved: ISTODAX — Original Application (Celgene Corporation)

  The FDA granted original approval for ISTODAX (romidepsin) to Celgene. The approval covered treatment for cutaneous T-cell lymphoma, includi…